Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

4.042 +0.072 (+1.81%)

Streaming Delayed Price Updated: 11:18 AM EDT, Jul 6, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	27,475
Open	4.000
Bid (Size)	3.960 (200)
Ask (Size)	4.150 (300)
Prev. Close	3.970
Today's Range	3.950 - 4.185
52wk Range	1.110 - 5.744
Shares Outstanding	11,184,423
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

New to The Street Show #760 Airs Tonight on Bloomberg Television Across the U.S. on Independence Day Featuring Sullivan & Cromwell’s Frank Aquila, Medicus Pharma, PetVivo, FreeCast and YY Group

July 04, 2026

From New to The Street

Via ACCESS Newswire

New to The Street Announces Broadcast of Show #759 on Bloomberg Television Across the U.S., MENA and Latin America tonight 630pm est.

June 27, 2026

From New to The Street

Via ACCESS Newswire

Performance

YTD	+30.0%	+30.0%
1 Month	+12.6%	+12.6%
3 Month	+149.5%	+149.5%
6 Month	+24.4%	+24.4%
1 Year	+28.3%	+28.3%

More News

New to The Street Broadcasts Tonight on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM ET

June 06, 2026

Via ACCESS Newswire

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Phase 2 HARMONIC Trial Data Supporting LP-300 in EGFR-Mutant Lung Cancer

June 02, 2026

Via Investor Brand Network

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

June 02, 2026

From Lantern Pharma Inc.

Via Business Wire

New to The Street Broadcasts Nationwide on Bloomberg Television Featuring "Opportunities To Consider(TM)" Across Artificial Intelligence, Healthcare Innovation, Fintech, Digital Assets, and Commodities

May 30, 2026

Via ACCESS Newswire

New to The Street Broadcasts Episode 753 Today at 6:30 PM EST Across Bloomberg Television U.S., MENA, and Latin America Featuring Leaders in VR Defense Training, AI Streaming, Healthcare Innovation, and Global Workforce Technology

May 23, 2026

Via ACCESS Newswire

Lantern Pharma (LTRN) Q1 2025 Earnings Transcript ↗

May 21, 2026

Via The Motley Fool

InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives FDA Support for HARMONIC(TM) Trial Amendments in Never-Smoker NSCLC

May 19, 2026

Via Investor Brand Network

Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC

May 19, 2026

From Lantern Pharma Inc.

Via Business Wire

AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q1 2026 Results, Advances Clinical Pipeline and AI Commercialization Strategy

May 18, 2026

Via Investor Brand Network

Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates

May 15, 2026

From Lantern Pharma Inc.

Via Business Wire

AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Closes $4.4 Million Registered Direct Offering

May 15, 2026

Via Investor Brand Network

Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

May 14, 2026

From Lantern Pharma Inc.

Via Business Wire

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Enters $4.4 Million Registered Direct Offering

May 13, 2026

Via Investor Brand Network

Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

May 13, 2026

From Lantern Pharma Inc.

Via Business Wire

MissionIRNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Report First Quarter 2026 Financial Results May 15

May 12, 2026

Via Investor Brand Network

Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026

May 11, 2026

From Lantern Pharma Inc.

Via Business Wire

InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Expands withZeta.ai Roadmap With Multi-Agent AI and Computational Biology Tools

May 07, 2026

Via Investor Brand Network

Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™

May 07, 2026

From Lantern Pharma Inc.

Via Business Wire

MissionIRNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Expands predictBBB Platform Into Large Quantitative Model for Drug Discovery

April 29, 2026

Via Investor Brand Network

Lantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally

April 29, 2026

From Lantern Pharma Inc.

Via Business Wire

New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global

April 25, 2026

Via ACCESS Newswire

AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Host Live Public Demo of withZeta.ai AI Co-Scientist Platform

April 24, 2026

Via Investor Brand Network

CORRECTION: Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers

April 24, 2026

Via ACCESS Newswire

Frequently Asked Questions

Is Lantern Pharma Inc. - Common Stock publicly traded?

Yes, Lantern Pharma Inc. - Common Stock is publicly traded.

What exchange does Lantern Pharma Inc. - Common Stock trade on?

Lantern Pharma Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Lantern Pharma Inc. - Common Stock?

The ticker symbol for Lantern Pharma Inc. - Common Stock is LTRN on the Nasdaq Stock Market

What is the current price of Lantern Pharma Inc. - Common Stock?

The current price of Lantern Pharma Inc. - Common Stock is 4.042

When was Lantern Pharma Inc. - Common Stock last traded?

The last trade of Lantern Pharma Inc. - Common Stock was at 07/06/26 11:18 AM ET

What is the market capitalization of Lantern Pharma Inc. - Common Stock?

The market capitalization of Lantern Pharma Inc. - Common Stock is 45.21M

How many shares of Lantern Pharma Inc. - Common Stock are outstanding?

Lantern Pharma Inc. - Common Stock has 45M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.